Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Advair Generic Looms, But GSK Says Growth Will Return Regardless

This article was originally published in The Pink Sheet Daily

Executive Summary

CEO Andrew Witty reconfirmed that GSK’s respiratory business will return to growth in 2016 and said the company’s five-year outlook does not depend on the timing of a generic Advair. Mylan recently filed what is believed to be the first ANDA for a generic Advair Diskus in the US.

You may also be interested in...



Teva Under Pressure As NICE Calls For More Reslizumab Analyses

UK HTA body NICE has called for clarifications and updated analyses in draft guidance on Teva’s MAb biologic Cinqaero, a decision that may give heart to potential competitors in the race to dominate the eosinophilic asthma market.

Swapping Assets Now Down To Execution For GSK And Novartis

Being successful with products originally marketed by the other will be key to the future growth and bragging rights for two leading European Big Pharmas, GlaxoSmithKline and Novartis.

Advair Generics Likely Lucrative Product For Few That Can Clear High Bar

With release of draft bioequivalence guidance for GSK’s blockbuster asthma and COPD treatment, generics seem more likely than ever, but there may be only a select number of companies who can meet the guidance’s requirements.

Topics

Related Companies

UsernamePublicRestriction

Register

LL1135495

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel